Trial Profile
Safety and Immunogenicity of Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose, Influenza Vaccines, 2018-2019 Formulations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza virus RIV4 vaccine-(FluBlok Quadrivalent) (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 10 Dec 2018 Status changed from recruiting to completed.
- 26 Sep 2018 Planned number of patients changed from 240 to 120.
- 26 Sep 2018 Status changed from not yet recruiting to recruiting.